You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

daSATinib

( da-SAT-in-ib )
Funding:
Exceptional Access Program
  • daSAtinib - PH+ ALL, with specific criteria
  • daSAtinib - Ph+ CML in the chronic phase, with specific criteria
  • daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Other Name(s): Sprycel®
Appearance: tablet In various strengths

You might also be interested in